High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

Izidore Lossos, Peter Hosein, Daniel Morgensztern, Francine Coleman, Maricer P. Escalón, Gerald E. Byrne, Joseph D Rosenblatt, Gail R. Walker

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.

Original languageEnglish
Pages (from-to)406-414
Number of pages9
JournalLeukemia and Lymphoma
Volume51
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Mantle-Cell Lymphoma
Ifosfamide
Thalidomide
National Cancer Institute (U.S.)
Cytarabine
Vincristine
Etoposide
Methotrexate
Doxorubicin
Cyclophosphamide
Mesna
Disease-Free Survival
Sepsis
Maintenance
Rituximab
Recurrence
Therapeutics

Keywords

  • Chemotherapy
  • Mantle cell lymphoma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{3e887fafb2824ff88559288868e8534f,
title = "High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma",
abstract = "Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.",
keywords = "Chemotherapy, Mantle cell lymphoma, Thalidomide",
author = "Izidore Lossos and Peter Hosein and Daniel Morgensztern and Francine Coleman and Escal{\'o}n, {Maricer P.} and Byrne, {Gerald E.} and Rosenblatt, {Joseph D} and Walker, {Gail R.}",
year = "2010",
month = "3",
day = "1",
doi = "10.3109/10428190903518345",
language = "English",
volume = "51",
pages = "406--414",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

AU - Lossos, Izidore

AU - Hosein, Peter

AU - Morgensztern, Daniel

AU - Coleman, Francine

AU - Escalón, Maricer P.

AU - Byrne, Gerald E.

AU - Rosenblatt, Joseph D

AU - Walker, Gail R.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.

AB - Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.

KW - Chemotherapy

KW - Mantle cell lymphoma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=77249120575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249120575&partnerID=8YFLogxK

U2 - 10.3109/10428190903518345

DO - 10.3109/10428190903518345

M3 - Article

C2 - 20038221

AN - SCOPUS:77249120575

VL - 51

SP - 406

EP - 414

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -